CPRX Financial Facts

Net loss: -5.39M
Loss per share - basic and diluted: -0.07
See Full Income Statement

Cash and cash equivalents: 22.23M
Deficit accumulated during the development stage: -95.46M
See Full Balance Sheet

Catalyst Pharmaceutical Partners Inc. (CPRX) Earnings

  |   Expand Research on CPRX
Next EPS Date 8/10/16 *Est. EPS Growth Rate 0.0% *Last Qtr.
Average EPS % Beat Rate +13.4% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS -1.1% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/10/16 Q116 -$0.07-$0.07 $0.00N/AN/A N/A Details
3/15/16 Q415 -$0.07-$0.07 $0.00N/AN/A N/A Details
11/9/15 Q315 -$0.05-$0.07 +$0.02N/AN/A N/A Details
8/10/15 Q215 -$0.06-$0.08 +$0.02N/AN/A N/A Details
5/11/15 Q115 -$0.07-$0.09 +$0.02N/AN/A N/A Details
3/16/15 Q414 -$0.06-$0.07 +$0.01N/AN/A N/A Details
11/14/14 Q314 -$0.06-$0.05 -$0.01N/AN/A N/A Details
8/14/14 Q214 -$0.05-$0.07 +$0.02N/AN/A N/A Details